| 书目名称 | Hematopoietic Growth Factors in Oncology |
| 编辑 | Gary H. Lyman,David C. Dale |
| 视频video | |
| 概述 | Illustrates the progress resulted from advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments |
| 丛书名称 | Cancer Treatment and Research |
| 图书封面 |  |
| 描述 | .Progress in the treatment of cancer over the past two decades has been rapid with many new and novel therapeutic modalities arriving at an unprecedented pace. Overall cancer mortality rates have actually begun to fall in parallel with progress in the diagnosis and treatment of malignant disease. Despite our advances in the understanding of the biology and molecular genetics of cancer, as well as the availability of an increasing array of effective therapies, cancer treatment today and for the foreseeable future will include the traditional modalities of surgery, radiation therapy and chemotherapy. Myelosuppressive agents with their potential hematopoietic toxicities remain the mainstay of systemic treatment for both metastatic and early stage cancer. The complications of cancer chemotherapy have serious impact on a patient’s well being and overall quality of life. Fortunately, advances in cancer treatment have been accompanied by equally impressive progress in the availability of a wide array of supportive care modalities which have greatly enhanced the ability of oncologists to minimize the impact of cancer and its treatment on patient quality of life as well improve delivery of |
| 出版日期 | Book 2011 |
| 关键词 | Biology; Molecular Genetics; Pharmacology |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-1-4419-7073-2 |
| isbn_softcover | 978-1-4614-2728-5 |
| isbn_ebook | 978-1-4419-7073-2Series ISSN 0927-3042 Series E-ISSN 2509-8497 |
| issn_series | 0927-3042 |
| copyright | Springer Science+Business Media, LLC 2011 |
发表于 2025-3-21 17:53:41
